Comprehensive Neurotransmitter Profile - Random
The Comprehensive Neurotransmitter Profile – Random measures urinary serotonin, dopamine, noradrenaline, adrenaline, GABA, glutamate, glycine, histamine, and phenylethylamine by LC-MS. Offered by Doctor's Data, it is a functional tool to explore mood, anxiety, focus, and stress biochemistry;
9
Biomarkers
Urine (random)
Sample
10–14 business days
Turnaround
No
Fasting
What is the Neurotransmitter Profile test?
The Comprehensive Neurotransmitter Profile – Random measures urinary concentrations of nine neurotransmitters and neuroactive amines — serotonin, dopamine, noradrenaline, adrenaline, GABA, glutamate, glycine, histamine, and phenylethylamine — by liquid chromatography–mass spectrometry. It is offered by Doctor's Data as a functional-medicine tool to explore mood, anxiety, focus, sleep, and stress-related symptoms and to guide personalised nutritional and nutraceutical interventions. Practitioners order this profile when seeking biochemical correlates of neuropsychiatric complaints in patients who have not responded to standard care or who prefer integrative approaches. Because peripheral neurotransmitter metabolites do not directly reflect brain neurotransmission — serotonin, GABA, and glutamate cannot cross the blood–brain barrier, and urinary concentrations reflect whole-body turnover, diet, gut flora, and renal handling — the panel is exploratory and hypothesis-generating rather than diagnostic. It is not a substitute for established psychiatric evaluation or neurological work-up, and its interpretation relies on functional-medicine models that are not universally accepted in mainstream neurology or psychiatry.
What does the Neurotransmitter Profile test measure?
Serotonin is synthesised primarily in enterochromaffin cells of the gastrointestinal tract and in serotonergic neurones of the central nervous system. Peripheral serotonin does not cross the blood–brain barrier, so urinary serotonin reflects largely gut and platelet turnover. Metabolism proceeds via monoamine oxidase to 5-hydroxyindoleacetic acid, the principal urinary metabolite.
Urinary serotonin is one marker in a broader neurotransmitter panel and is most often ordered in the functional-medicine context to explore mood, gastrointestinal, and sleep complaints. Because peripheral serotonin does not directly reflect brain neurotransmission, interpretation is exploratory and should not replace established psychiatric or neurological evaluation.
Dopamine is a catecholamine neurotransmitter synthesised from tyrosine in dopaminergic neurones and the adrenal medulla. It is a precursor of noradrenaline and adrenaline, with key roles in reward, motivation, motor control, and neuroendocrine regulation. Urinary dopamine reflects whole-body turnover and is metabolised to homovanillic acid.
Urinary dopamine in this profile is used to explore motivation, focus, and motor symptoms in a functional context. Diagnostic elevation occurs with phaeochromocytoma, but such cases are typically pursued via plasma or 24-hour urine metanephrines rather than a random neurotransmitter panel.
Noradrenaline is synthesised from dopamine in sympathetic neurones and the adrenal medulla, acting as both a neurotransmitter and a hormone. It drives the sympathetic stress response, elevating heart rate, blood pressure, and alertness. Metabolism proceeds via catechol-O-methyltransferase and monoamine oxidase to normetanephrine and vanillylmandelic acid.
Noradrenaline in this panel is interpreted as a marker of sympathetic tone and stress reactivity. High values may reflect acute stress, anxiety, or increased sympathetic activity; low values may suggest adrenal fatigue or HPA-axis dysfunction in functional models, though these constructs lack validation in mainstream endocrinology.
Adrenaline is synthesised from noradrenaline in the adrenal medulla and to a lesser extent in some central neurones. It mediates the acute fight-or-flight response, mobilising glucose and fatty acids and increasing cardiac output. Urinary adrenaline reflects adrenal secretion and is metabolised to metanephrine.
Adrenaline is used in this profile to assess acute stress and adrenal output. Diagnostic elevation is seen with phaeochromocytoma and is pursued via plasma or 24-hour metanephrines; the random panel here is exploratory.
GABA is the principal inhibitory neurotransmitter in the central nervous system, synthesised from glutamate by glutamic acid decarboxylase. Peripheral GABA is produced in the gut and other tissues but does not cross the blood–brain barrier, so urinary GABA does not directly reflect brain GABA tone.
GABA in this panel is used to explore anxiety, sleep, and seizure disorders in a functional context. Because blood–brain-barrier impermeability means peripheral GABA does not mirror central neurotransmission, interpretation is speculative and not a replacement for clinical neuropsychiatric assessment.
Glutamate is the principal excitatory neurotransmitter in the brain and a key metabolic intermediate. It is synthesised from glutamine and alpha-ketoglutarate, and its receptor signalling underpins learning, memory, and neuronal plasticity. Peripheral glutamate is abundant in diet and tissues; like GABA, blood glutamate does not cross the blood–brain barrier.
Urinary glutamate in this panel is used to explore excitotoxicity, anxiety, and cognitive symptoms in functional models. Peripheral glutamate does not reflect brain levels, so interpretation is exploratory.
Glycine is the simplest amino acid, acting both as a building block of proteins and as an inhibitory neurotransmitter in the spinal cord and brainstem. It is synthesised from serine and threonine and participates in glutathione synthesis and one-carbon metabolism.
Glycine in this neurotransmitter profile is interpreted as an inhibitory signal. Elevations may suggest impaired metabolism or overflow from dietary or endogenous sources; low values are sometimes linked to sleep and mood disturbance in functional models.
Histamine is a biogenic amine synthesised by decarboxylation of histidine, with roles in immune response, gastric acid secretion, and neurotransmission. It is stored in mast cells and basophils, released on degranulation, and metabolised by histamine N-methyltransferase and diamine oxidase to methylhistamine and imidazole acetic acid.
Urinary histamine in this panel is used to explore mast-cell activation, allergy, and histamine intolerance. Elevation may reflect mast-cell degranulation, dietary histamine, or impaired clearance; low values are less commonly interpreted.
Phenylethylamine is a trace amine synthesised from phenylalanine by aromatic amino-acid decarboxylase. It modulates catecholamine release and receptor sensitivity, with a very short half-life, and is metabolised by monoamine oxidase B. It has been called an endogenous amphetamine due to its structural and functional similarity.
PEA in this profile is used to explore mood, attention, and reward processing. Low values are sometimes associated with depression and attention deficits in functional models, but the evidence base is limited and interpretation is exploratory.
Why is the Neurotransmitter Profile test ordered?
- Patients with treatment-resistant depression, anxiety, or mood instability seeking integrative or functional-medicine assessment
- Exploration of cognitive symptoms such as poor focus, memory difficulty, or brain fog in the absence of structural neurological findings
- Sleep disturbance — insomnia, non-restorative sleep, or circadian misalignment — where neurotransmitter imbalance is suspected
- Suspected mast-cell activation or histamine intolerance presenting with flushing, gastrointestinal upset, headache, and anxiety
- Assessment of stress reactivity and HPA-axis function in chronic fatigue or burnout, interpreted with adrenal testing
- Guided amino-acid and cofactor supplementation in functional or integrative practice, where the panel informs dosing of precursors such as 5-hydroxytryptophan, tyrosine, or GABA
- Patients with autism spectrum disorder, ADHD, or other developmental conditions in whom practitioners seek biochemical phenotyping
- Follow-up monitoring of neurotransmitter-directed interventions to assess biochemical response
Sample collection and turnaround
Sample type
Urine (random)
Fasting required
No
Collection method
At-home collection kit
Turnaround
10–14 business days
Collection notes
Doctor's Data provides a random urine collection kit shipped to the patient. Ideally collect a mid-morning void to minimise diurnal extremes. Avoid high-protein, amine-rich meals and supplements for 24–48 hours before collection, and where feasible pause medications affecting monoamine metabolism (consult the prescribing clinician). Collect into the provided container, note collection time, and return via the prepaid shipper on the same day; refrigerate if delayed.
Specimen requirements
Minimum 10 mL random urine. Freeze if storage exceeds 24 hours before shipping. Doctor's Data uses proprietary LC-MS methodology, so specimen handling and stability follow the laboratory's protocol.
What can affect Neurotransmitter Profile results?
High-protein meals, tyrosine- and tryptophan-rich foods, and histamine-containing foods (aged cheese, fermented products, wine) can raise urinary amine concentrations independent of endogenous synthesis.
MAO inhibitors, SSRIs, SNRIs, tricyclics, and stimulants alter neurotransmitter synthesis, release, reuptake, and degradation, confounding baseline assessment. A medication history is essential.
Gut bacteria synthesise and metabolise neurotransmitters and their precursors; dysbiosis, SIBO, and altered gut permeability can shift urinary amine profiles independent of neurological function.
Acute stress, pain, anxiety, and physical exertion raise catecholamine secretion, so collection during a calm, rested state improves baseline interpretation.
Glomerular filtration and tubular handling affect excretion; creatinine normalisation adjusts for dilution, but hydration extremes and renal disease can still alter results.
Neurotransmitter metabolism shows diurnal rhythms; a random collection captures a single time point and may not reflect daily patterns, unlike 24-hour collections.
What do Neurotransmitter Profile results mean?
Elevated
Elevated serotonin may suggest carcinoid tumour (rare, typically pursued via 5-HIAA), high dietary tryptophan, or gut serotonin overproduction. High catecholamines (dopamine, noradrenaline, adrenaline) may reflect acute stress, phaeochromocytoma (pursue with plasma metanephrines if suspected), or sympathetic overdrive. Elevated glutamate and low GABA together may be interpreted as excitatory dominance in functional models. High histamine suggests mast-cell activation, histamine intolerance, or dietary load.
Normal
Results within laboratory ranges do not exclude neuropsychiatric disease — mood and anxiety disorders are clinical diagnoses, and urinary neurotransmitter concentrations are not validated diagnostic criteria. A normal profile may reassure that gross biochemical imbalance is absent or may prompt exploration of other pathways.
Reduced
Low serotonin is sometimes associated with depression and poor sleep in functional models, though peripheral serotonin does not cross the blood–brain barrier. Low catecholamines may suggest inadequate precursor availability, HPA-axis dysfunction, or low sympathetic tone. Low GABA and glycine are interpreted as insufficient inhibitory tone, linked to anxiety and insomnia. Low PEA is associated with depression and attention deficits in exploratory models.
Note: This panel is a functional tool, not a diagnostic test. Peripheral neurotransmitter metabolites do not directly reflect brain neurotransmission due to the blood–brain barrier, and reference intervals are laboratory- and method-specific. Interpretation relies on functional-medicine models that are exploratory and not universally accepted. The panel should complement, not replace, psychiatric and neurological evaluation, and practitioners must integrate results with clinical context, medication history, diet, and gut health.
Frequently asked questions
No. Serotonin, GABA, and glutamate do not cross the blood–brain barrier, so urinary concentrations reflect peripheral synthesis, gut production, and whole-body turnover rather than brain neurotransmission. The panel is exploratory and functional rather than diagnostic.
How to access the Neurotransmitter Profile test
The Neurotransmitter Profile reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: October 7, 2026
Last reviewed: October 7, 2026
- Eisenhofer G, et al. Biochemical diagnosis of phaeochromocytoma: plasma versus urinary fractionated metanephrines. Journal of Clinical Endocrinology & Metabolism. (2003)
- Hyland K. Clinical utility of monoamine neurotransmitter metabolite analysis in cerebrospinal fluid. Clinical Chemistry. (2008)
- Branchek TA, Blackburn TP. Trace amine receptors as targets for novel therapeutics: legend, myth and fact. Current Opinion in Pharmacology. (2003)
- Jenkins TA, et al. Influence of tryptophan and serotonin on mood and cognition with a possible role of the gut–brain axis. Nutrients. (2016)
- Yano JM, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. (2015)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.